Tharimmune announces phase 2 study plan for th104 in patients with moderate-to-severe pruritus associated with primary biliary cholangitis and provides a business update

Bridgewater, nj / accesswire / december 16, 2024 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a phase 2 study evaluating th104 in patients suffering from moderate-to-severe pruritus (severe itching) associated with primary biliary cholangitis (pbc), a rare and chronic liver disease, and also provided a corporate update. the launch of this clinical trial, expected in 2025, follows favorable results from tharimmune's phase 1 study with th104, recent regulatory feedback from the european medicines agency (ema) and the u.s. food and drug administration (fda), as well as progress on manufacturing clinical study supply.
THAR Ratings Summary
THAR Quant Ranking